CNS PHARMACEUTICALS, INC. (CNSP): Price and Financial Metrics


CNS PHARMACEUTICALS, INC. (CNSP)

Today's Latest Price: $2.30 USD

0.07 (-2.95%)

Updated Nov 24 4:00pm

Add CNSP to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

CNSP Stock Price Chart Interactive Chart >

Price chart for CNSP

CNSP Price/Volume Stats

Current price $2.30 52-week high $5.62
Prev. close $2.37 52-week low $1.26
Day low $2.21 Volume 213,700
Day high $2.53 Avg. volume 113,089
50-day MA $1.92 Dividend yield N/A
200-day MA $2.52 Market Cap 38.30M

CNS PHARMACEUTICALS, INC. (CNSP) Company Bio


CNS Pharmaceuticals, Inc. is a preclinical stage pharmaceutical company, which engages in the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. Its product pipeline includes berubicin, and CNS-12. The company was founded by Waldemar Priebe in July 2017 and is headquartered in Houston, TX.


CNSP Latest News Stream


Event/Time News Detail
Loading, please wait...

CNSP Latest Social Stream


Loading social stream, please wait...

View Full CNSP Social Stream

Latest CNSP News From Around the Web

Below are the latest news stories about CNS Pharmaceuticals Inc that investors may wish to consider to help them evaluate CNSP as an investment opportunity.

CNS Pharmaceuticals Achieves Critical Manufacturing Milestone

HOUSTON, Oct. 1, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that the…

PR Newswire | October 1, 2020

CNS Pharmaceuticals to Present at the H.C. Wainwright & Co. 22nd Annual Global Investment Conference

HOUSTON, Sept. 11, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, today announced that CEO, John…

PR Newswire | September 11, 2020

CNS Pharmaceuticals Recognizes Glioblastoma Awareness Day

HOUSTON, July 22, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today recognizes…

PR Newswire | July 22, 2020

CNS Pharmaceuticals Completes Drug Product Manufacturing Strategy for Berubicin

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today provided an update on the manufacturing strategy for Berubicin drug product, its lead drug candidate for the treatment of glioma brain tumors.

Yahoo | July 15, 2020

CNS Pharmaceuticals Completes Active Ingredient Shipments to Manufacturers

HOUSTON, July 8, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, announced today it has…

PR Newswire | July 8, 2020

Read More 'CNSP' Stories Here

CNSP Price Returns

1-mo 27.07%
3-mo -8.00%
6-mo -13.53%
1-year -43.77%
3-year N/A
5-year N/A
YTD -41.77%
2019 N/A
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7104 seconds.